Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102882
Status:
COMPLETED
Last Update Posted:
2017-02-03
First Post:
2005-02-03
Brief Title:
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone PropionateSalmeterol Or Salmeterol Xinafoate
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Randomized Double-Blind Comparison of Advair 10050 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARGARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study may last up to 36-38 weeks Patients will visit the clinic 11 times A blood sample will be taken at Visit 1 to look at subjects genes Breathing tests will be done during the study Study medicines and procedures will be provided at no cost Patients will be treated with VENTOLIN 8 wks ATROVENT 8 wks then ADVAIR or SEREVENT 16 wks ADVAIR and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and older
Detailed Description:
A Randomized Parallel Group Double-Blind Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents at least 12 Years of Age with Persistent Asthma Who Have Either a B16-ArgArg a B16-GlyGly or a B-16 ArgGly Genotype and are Treated With Fluticasone PropionateSalmeterol DISKUS Combination Product 10050mcg or Salmeterol DISKUS 50 mcg BID
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None